跳至主要内容
临床试验/NCT00111644
NCT00111644已完成2 期

A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia

Hoffmann-La Roche0 个研究点目标入组 302 人开始时间: 2005年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
302
主要终点
Clinical cure rate\n\n

研究概览

简要总结

This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female patients at least 18 years of age;
  • hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason;
  • new or increased productive cough;
  • chest pain, shortness of breath, or rapid breathing.

排除标准

  • requiring intubation or ventilation;
  • nursing home or extended care within 60 days before study;
  • concomitant bacterial infection requiring antibiotics;
  • long-term immunosuppressive therapy.

研究组 & 干预措施

1

Experimental

干预措施: beta-lactam (Drug)

2

Experimental

干预措施: beta-lactam (Drug)

3

Active Comparator

干预措施: Ceftriaxone (Drug)

结局指标

主要结局

Clinical cure rate\n\n

时间窗: End of study visit (7-10 days after end of treatment)

次要结局

  • Adverse events, vital signs, laboratory parameters\n(Throughout study)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验